Advertisement

Journal of Neurology

, Volume 262, Issue 7, pp 1646–1654 | Cite as

25-Hydroxyvitamin D levels in acute monosymptomatic optic neuritis: relation to clinical severity, paraclinical findings and risk of multiple sclerosis

  • Gorm Pihl-JensenEmail author
  • Jette Lautrup Frederiksen
Original Communication

Abstract

Optic neuritis (ON) is a common first symptom of MS and only few studies have thus far investigated vitamin D at this early stage of MS. The objectives of the study were to examine total 25-hydroxyvitamin D levels (25HVITDL) in patients in acute (A) ON and to determine whether 25HVITD levels in AON (1) predict risk of RRMS and (2) are associated with visual tests of ON severity. A cross-sectional study was conducted of mean 25HVITDL differences between ON (n = 164) and MS (n = 948) patients and of prevalence of 25HVITDL deficiency (<50 nmol/L) in ON and MS (two-sample t test, χ 2 test). Associations between 25HVITDL and (1) clinical ON severity, (2) paraclinical findings suggestive of MS [logistic regression (LRA), Spearman correlation] and (3) hazard of MS development [Cox (C) RA] in ON patients were assessed. 25HVITDL were deseasonalized before analysis. The mean levels were 47.6 (ON) and 63.9 (MS) nmol/L (p < 0.0001), and a significantly higher prevalence of 25HVITD deficiency in ON (56 %; 35 %) (p < 0.0001), most pronounced in females, was shown. Associations were found between 25HVITDL and both CSF leukocyte count (ρ = −0.177, p = 0.028) and IgG index elevation (OR 0.980, p = 0.031). Forty-one ON patients developed MS during the study. Multivariate CRA showed no effect on hazard of MS (HR: 0.991, p 0.284). No association was found between 25HVITDL and visual tests (acuity, contrast vision) or OCT RNFL or GCL thickness. The study indicates a high prevalence of 25HVITD deficiency in AON. 25HVITDL was significantly associated with CSF leukocyte count, but not ON severity. The study indicates a possible role of vitamin D in the early stages of MS, but does not support the use of 25HVITDL as a predictor of MS development in acute ON.

Keywords

Multiple sclerosis Optic neuritis Clinically isolated syndrome Vitamin D 

Notes

Conflicts of interest

Dr. Pihl-Jensen reports no disclosures. Dr. Frederiksen has served on a scientific advisory board and received funding for travel related to these activities and honoraria from Biogen Idec, Merck Serono, Teva Pharmaceutical Industries Ltd., Sanofi-Aventis, Novartis, Genzyme and Almirall. Jette Frederiksen has received speaker honoraria from Biogen Idec, Merck Serono and Teva. She has served as advisor on preclinical development for Takeda.

Ethical standard

The study was approved by the Danish Health and Medicines Authority and the Danish Data Protection Agency. Due to the retrospective study design, approval from research ethics committee was not required.

References

  1. 1.
    Ascherio A (2013) Environmental factors in multiple sclerosis. Expert Rev Neurother 13:3–9CrossRefPubMedGoogle Scholar
  2. 2.
    Smolders J, Moen SM, Damoiseaux J, Huitinga I, Holmoy T (2011) Vitamin D in the healthy and inflamed central nervous system: access and function. J Neurol Sci 311:37–43CrossRefPubMedGoogle Scholar
  3. 3.
    Meehan TF, DeLuca HF (2002) The vitamin D receptor is necessary for 1 alpha, 25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys 408:200–204CrossRefPubMedGoogle Scholar
  4. 4.
    Cantorna MT, Hayes CE, DeLuca HF (1996) 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 93:7861–7864PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Hoorbakht H, Bagherkashi F (2012) Optic neuritis, its differential diagnosis and management. Open Ophthalmol J 6:65–72PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Optic Neuritis Study Group (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65:727–732Google Scholar
  7. 7.
    Nilsson P, Larsson EM, Maly-Sundgren P, Perfekt R, Sandberg-Wollheim M (2005) Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol 252:396–402CrossRefPubMedGoogle Scholar
  8. 8.
    Marques IB, Matias F, Silva ED, Cunha L, Sousa L (2014) Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. J Clin Neurosci 21:583–586CrossRefPubMedGoogle Scholar
  9. 9.
    Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P, Bucci M, Hauser SL, Pelletier D (2012) Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 72:234–240PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P, van der Mei I (2010) Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 68:193–203PubMedGoogle Scholar
  11. 11.
    Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ (2012) Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 79:261–266CrossRefPubMedGoogle Scholar
  12. 12.
    Malik MT, Healy BC, Benson LA, Kivisakk P, Musallam A, Weiner HL, Chitnis T (2014) Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology 82:2173–2179PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Munger KL, Zhang SM, O’Reilly E, Hernan MA, Olek MJ, Willett WC, Ascherio A (2004) Vitamin D intake and incidence of multiple sclerosis. Neurology 62:60–65CrossRefPubMedGoogle Scholar
  14. 14.
    Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ (2011) A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 77:1611–1618CrossRefPubMedGoogle Scholar
  15. 15.
    Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H (2012) Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012:452541PubMedCentralPubMedGoogle Scholar
  16. 16.
    Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P (2011) Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest 40:627–639CrossRefPubMedGoogle Scholar
  17. 17.
    Soilu-Hanninen M, Aivo J, Lindstrom BM, Elovaara I, Sumelahti ML, Farkkila M, Tienari P, Atula S, Sarasoja T, Herrala L, Keskinarkaus I, Kruger J, Kallio T, Rocca MA, Filippi M (2012) A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 83:565–571CrossRefPubMedGoogle Scholar
  18. 18.
    Aivo J, Lindsrom BM, Soilu-Hanninen M (2012) A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Mult Scler Int 2012:802796PubMedCentralPubMedGoogle Scholar
  19. 19.
    Ascherio A, Munger KL, White R, Kochert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalban X, Edan G, Barkhof F, Pleimes D, Radu EW, Sandbrink R, Kappos L, Pohl C (2014) Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 71:306–314PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Martinelli V, Dalla Costa G, Colombo B, Dalla Libera D, Rubinacci A, Filippi M, Furlan R, Comi G (2014) Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 20:147–155CrossRefPubMedGoogle Scholar
  21. 21.
    Etemadifar M, Abtahi SH, Razmjoo H, Abtahi MA, Dehghani A, Salari M, Maghzi AH, Akbari M (2012) 25-Hydroxyvitamin D concentrations in patients with optic neuritis as a clinically isolated syndrome and healthy controls. Int J Prev Med 3:313–317PubMedCentralPubMedGoogle Scholar
  22. 22.
    Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, McDonald JC, Oksenberg JR, Bacchetti P, Waubant E (2010) Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 67:618–624PubMedGoogle Scholar
  23. 23.
    Derakhshandi H, Etemadifar M, Feizi A, Abtahi SH, Minagar A, Abtahi MA, Abtahi ZA, Dehghani A, Sajjadi S, Tabrizi N (2013) Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol Belg 113:257–263CrossRefPubMedGoogle Scholar
  24. 24.
    Hupperts R (2014) Supplementation of VigantOL® oil versus placebo as add-on in patients with relapsing remitting multiple sclerosis receiving Rebif® treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401. Accessed 01 Dec 2014
  25. 25.
    Dorr J, Ohlraun S, Skarabis H, Paul F (2012) Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 13:15PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Hutchinson M (2012) Dose-related Effects of vitamin D3 on immune responses in patients with clinically isolated syndrome (CISAVID). https://clinicaltrials.gov/ct2/show/NCT01728922. Accessed 01 Dec 2014
  27. 27.
    Carroll W (2013) Preventing the risk of multiple sclerosis using vitamin D in patients with a first demyelinating event in Australia and New Zealand (PrevANZ). http://www.msra.org.au/prevanz. Accessed 01 Dec 2014
  28. 28.
    Thouvennot E (2013) Efficacy of cholecalciferol (vitamin D3) for delaying the diagnosis of MS after a clinically isolated syndrome (D-Lay-MS). https://clinicaltrials.gov/ct2/show/NCT01817166?term=vitamin+d+clinically+isolated+syndrome&rank=22014. Accessed 01 Dec 2014
  29. 29.
    Modvig S, Degn M, Horwitz H, Cramer SP et al (2013) Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS One 8(10):e77163. doi: 10.1371/journal.pone.0077163 PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Jones G (2008) Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 88:582S–586SPubMedGoogle Scholar
  31. 31.
    van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, Butzkueven H, McMichael AJ (2007) Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254:581–590CrossRefPubMedGoogle Scholar
  32. 32.
    Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832–2838CrossRefPubMedGoogle Scholar
  33. 33.
    Sachs MC, Shoben A, Levin GP, Robinson-Cohen C, Hoofnagle AN, Swords-Jenny N, Ix JH, Budoff M, Lutsey PL, Siscovick DS, Kestenbaum B, de Boer IH (2013) Estimating mean annual 25-hydroxyvitamin D concentrations from single measurements: the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr 97:1243–1251PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Reiber H, Peter JB (2001) Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 184:101–122CrossRefPubMedGoogle Scholar
  35. 35.
    Hess KR (1995) Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 14:1707–1723CrossRefPubMedGoogle Scholar
  36. 36.
    Durup D, Jorgensen HL, Christensen J, Schwarz P, Heegaard AM, Lind B (2012) A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab 97:2644–2652CrossRefPubMedGoogle Scholar
  37. 37.
    Durup D, Jorgensen HL, Christensen J, Tjonneland A, Olsen A, Halkjaer J, Lind B, Heegaard AM, Schwarz P (2015) A reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality—the CopD-study. J Clin Endocrinol Metab (jc20144551) [Epub ahead of print]Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Gorm Pihl-Jensen
    • 1
    • 2
    Email author
  • Jette Lautrup Frederiksen
    • 1
    • 2
  1. 1.Clinic of Optic Neuritis, Department of NeurologyGlostrup Hospital, University of CopenhagenGlostrupDenmark
  2. 2.Clinic of Multiple Sclerosis, Department of NeurologyGlostrup Hospital, University of CopenhagenGlostrupDenmark

Personalised recommendations